Although all recommendations were endorsed, an expert panel also added discussion points regarding treatments for reducing skeletal-related events in and improving survival in patients with bone metastases.
A survey study sought to identify confidence levels among oncology nurse specialists in managing bone health of patients with cancer, and barriers to care.
Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study.
The epidemiology and pathophysiology of cancer-associated bone disease was reviewed in a new paper published by an International Osteoporosis Foundation (IOF) Committee of Scientific Advisors Working Group.
A review of calcium and vitamin D supplementation trials revealed that current recommended doses are inadequate to prevent bone mineral density loss in women undergoing breast cancer therapy.
FDA-related news items of relevance from the month of June, 2013.
When patients with giant-cell tumor of the bone were treated with denosumab, which is a drug targeted against a protein that promotes bone destruction, the number of tumor giant cells decreased and new bone formation increased.
Calcium and/or vitamin D supplementation at commonly recommended doses does not prevent bone loss from androgen-deprivation therapy.
Denosumab better prevents skeletal complications, ups health-related QoL versus zoledronic acid.
A history of periodontitis may be associated with an increased risk of HPV-positive tumors in persons with head and neck squamous cell carcinoma.
